Aurinia Pharmaceuticals Inc. (AUPH) Earnings
Aurinia Pharmaceuticals Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $0.21. AUPH has beaten EPS estimates in 10 of its last 12 reported quarters (average surprise +199.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $0.18 | $0.25 | +38.9% | $78M | +0.9% |
| Jul 31, 2025 | $0.17 | $0.16 | -5.9% | $70M | +3.4% |
| Feb 27, 2025 | $0.03 | $0.09 | +200.0% | $60M | -3.2% |
| Nov 7, 2024 | $0.01 | $0.10 | +566.7% | $68M | +4.2% |
| Aug 1, 2024 | $0.02 | $0.02 | +20.0% | $57M | +3.9% |
| May 2, 2024 | $-0.17 | $-0.03 | +82.4% | $50M | +6.0% |
| Nov 2, 2023 | $-0.17 | $-0.09 | +47.1% | $55M | +41.6% |
| Aug 3, 2023 | $-0.18 | $-0.08 | +55.6% | $41M | +8.8% |
| May 4, 2023 | $-0.22 | $-0.18 | +18.2% | $34M | +23.5% |
| Feb 28, 2023 | $-0.27 | $-0.18 | +33.3% | $28M | +2.4% |
| Nov 3, 2022 | $-0.17 | $-0.06 | +64.7% | $56M | +54.1% |
| Aug 4, 2022 | $-0.22 | $-0.25 | -13.6% | $28M | +4.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2025 · February 26, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Commercial growth: Strong Lucana sales in 2025 with 25% year - over - year growth. Arrhenia continues to drive growth in the commercial Loop Kindness business. - Clinical development: Excited about eritinracept, a dual BAF april inhibitor. It was well tolerated in phase one studies. Arrhenia has initiated a clinical study in one autoimmune disease and plans to initiate another in the first half of 2026. - Termination of studies: Terminated phase three and open - label studies in the vocal study and vocal extension, pediatric study due to technical issues in recruiting patients for the vocal study, but has data from in - market treatment of pediatric and adolescent patients and will negotiate with FDA for pediatric commitments.
Guidance
- 2026 guidance: Expect total revenue of $315 million to $325 million, up 11% to 15% compared to 2025. Expect net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. - 2025 vs 2026: 2025 had total revenue of $283.1 million and net product sales of $271.3 million. 2026 guidance is based on continued momentum of Loopkindness.
Segment performance
For the fourth quarter of 2025, total revenue was $77.1 million, up 29% from $59.9 million in 2024. Net product sales of Loop Kindness in Q4 2025 were $74.2 million, up 29% from $57.6 million in 2024. For the year ended December 31, 2025, total revenue was $283.1 million, up 20% from $235.1 million in 2024. Net product sales of Loop Kindness for the year were $271.3 million, up 25% from $216.2 million in 2024. Cash flows from operating activities in Q4 2025 were $45.7 million, up 52% from $30.1 million in 2024. For the year ended December 31, 2025, cash flows from operating activities were $135.7 million, up 206% from $44.4 million in 2024. Revenue contribution % isn't explicitly calculated but the focus is on the absolute financial performance of Loop Kindness and overall revenue.
Risks & headwinds
- Technical issues in clinical studies: Difficulty in recruiting patients for the vocal study led to termination of phase three and open - label studies. - Competitive landscape: New competitors like Gaziwa may impact the market, but Irinia believes in its competitive profile due to the speed and mechanism of action of Loop Kindness. - Regulatory uncertainties: Uncertainties around meeting pediatric commitments with the FDA and potential impacts of new regulations on the market.
Analyst Q&A
Q: Your issued guidance for 2026 seems somewhat conservative given the 4Q run rate. What are some of the specifics informing the commercial outlook and as it relates to what you're seeing in the first two months of this year?
A: Strategy hinges on changing the treatment and diagnostic paradigm for lupus nephritis using Loop Kindness's efficacy data. Not giving steer for the quarter but past history is a best predictor.
Q: You recently terminated the phase three and the open - level studies in the vocal study and the vocal extension, the pediatric study, and it mentioned like part DSMB recommendations. Can you clarify whether DSMB is asking to stop or is FDA refocused on the drug in any way?
A: Due to technical issues in recruiting patients for the vocal study, decision was made to terminate. Have data from in - market treatment of pediatric and adolescent patients and will negotiate with FDA for pediatric commitments.
Q: Previously you guys got into a development update for R10 or SIFT in early 2026. Can we still expect this update, and can you please provide some additional context for what this might entail?
A: We're excited about therapeutic potential of BAFAPRIL inhibition. Will disclose indications for studies in the second quarter of 2026.
Q: Giving the guidance for the 2036, how much the growth is coming from the rheumatologist versus the nephrologist?
A: Slightly favors rheumatologist, with more prescribers in the room space. Guidelines emphasize earlier diagnosis and aggressive treatment, which will impact growth from both.
Q: Have you seen any impact of the positioning of loop kinase in the treatment landscape following the launch of Gaziwa? And is the approval of Gaziwa incorporated in your guidance, and how do you think it will impact loop kinase going forward?
A: No near - term impact from Gaziwa launch. Guidance represents multiple factors. Loop Kindness has competitive profile with rapid reduction in proteinuria and complementary mechanism of action.
Q: Good morning, and congratulations on the quarter. I realize Leukinus was launched in the U.S. market first. Do you expect the other global markets will catch up to the U.S. as far as penetration in the lupus nephritis patient population?
A: No, due to different pricing, reimbursement, and guidelines in other markets.
Q: On ARIT Intercept, what's the cadence of updates that we should expect from that program? And given that you are looking at two indications, is there one that you maybe have higher conviction in or feel like your program has a better chance in?
A: Expect more in second quarter 2026. Don't have a preferential indication in mind in terms of probability for success.